Abstract
Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Current Drug Therapy
Title: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Volume: 6 Issue: 4
Author(s): Rajashree Hirlekar, Harshal Garse and Vilasrao Kadam
Affiliation:
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Abstract: Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Export Options
About this article
Cite this article as:
Hirlekar Rajashree, Garse Harshal and Kadam Vilasrao, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review, Current Drug Therapy 2011; 6(4) . https://dx.doi.org/10.2174/157488511798109637
DOI https://dx.doi.org/10.2174/157488511798109637 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Diet and Heart Health: Moderate Wine Drinking Strengthens the Cardioprotective Effects of Fish Consumption
Current Pharmaceutical Biotechnology The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Poly(ADP-ribose)polymerase Inhibition - Where Now?
Current Medicinal Chemistry Upstream Processing of Plasmid DNA for Vaccine and Gene Therapy Applications
Recent Patents on Biotechnology Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Tumor Markers: The Potential of “Omics” Approach
Current Molecular Medicine Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy NQDI 1, An Inhibitor of ASK1 Attenuates Acute Ischemic Renal Injury by Modulating Oxidative Stress and Cell Death
Cardiovascular & Hematological Agents in Medicinal Chemistry The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Epstein-Barr Virus Infection and its Pathogenetic Roles for Human Diseases
Current Pediatric Reviews Exploiting Endogenous Cellular Process to Generate Quinone Methides In Vivo
Current Organic Chemistry Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Drug Targets in Herpes Simplex and Epstein Barr Virus Infections
Infectious Disorders - Drug Targets